ANIP

ANI has crossed from a serial money-loser into a durably profitable specialty pharma. The five-year revenue arc (216M→316M→487M→614M→883M) is unbroken, and FY2025 finally converts at the bottom: net income swung to $78.3M (+522.9%), diluted EPS hit $3.32, and operating income reached $111M off a near-zero prior-year base. Cash generation is the real story — $185M operating cash flow against just $13.8M capex is ~$171M of free cash flow, roughly a 9% yield on the $1.89B market cap. GAAP margins look thin (12.6% operating, 8.9% net) precisely because $91.4M of D&A — up 35% — is mostly non-cash amortization of Alimera/ILUVIEN intangibles, so cash earnings materially exceed reported profit. The balance sheet supports the growth: $286M cash (+97%) nearly offsets ~$309M of debt for only ~$23M net debt, with the $75M revolver essentially undrawn.

The MD&A frames a coherent three-engine model — Rare Disease (Cortrophin Gel), Generics, and Brands (ILUVIEN/YUTIQ from the Sept-2024 Alimera deal) — and management has already expanded ILUVIEN's label to chronic NIU-PS and renegotiated the SWK royalty down to a fixed 3.125%, both incremental tailwinds. The honest caveat is that FY2025's +44% is flattered by a full year of Alimera versus a partial 2024; investors should treat the underlying organic rate as lower. Even so, at 25.3x trailing EPS and 2.1x sales for a business compounding double-digits with this FCF profile, the price is not demanding.